======= PCGF2 =======
== Gene Information ==
* **Official Symbol**: PCGF2
* **Official Name**: polycomb group ring finger 2
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7703|7703]]
* **UniProt**: [[https://www.uniprot.org/uniprot/P35227|P35227]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PCGF2&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PCGF2|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/600346|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Transcriptional repressor. Binds specifically to the DNA sequence 5'-GACTNGACT-3'. Has tumor suppressor activity. May play a role in control of cell proliferation and/or neural cell development. Regulates proliferation of early T progenitor cells by maintaining expression of HES1. Also plays a role in antero- posterior specification of the axial skeleton and negative regulation of the self-renewal activity of hematopoietic stem cells (By similarity). Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:26151332). Within the PRC1-like complex, regulates RNF2 ubiquitin ligase activity (PubMed:26151332). {ECO:0000250|UniProtKB:P23798, ECO:0000269|PubMed:26151332}.
|zf-C3HC4|
|sex chromatin|
|histone H2A-K119 monoubiquitination|
|PRC1 complex|
|histone H2A monoubiquitination|
|histone H2A ubiquitination|
|PcG protein complex|
|histone monoubiquitination|
|negative regulation of G0 to G1 transition|
|histone ubiquitination|
|regulation of G0 to G1 transition|
|promoter-specific chromatin binding|
|chromatin organization involved in negative regulation of transcription|
|chromatin silencing|
|protein monoubiquitination|
|chromatin organization involved in regulation of transcription|
|cellular response to hydrogen peroxide|
|negative regulation of gene expression, epigenetic|
|embryonic skeletal system morphogenesis|
|histone acetylation|
|cellular response to antibiotic|
|response to hydrogen peroxide|
|internal peptidyl-lysine acetylation|
|peptidyl-lysine acetylation|
|internal protein amino acid acetylation|
|embryonic skeletal system development|
|cellular response to reactive oxygen species|
|protein acetylation|
|gene silencing|
|protein acylation|
|response to reactive oxygen species|
|cellular response to toxic substance|
|anterior/posterior pattern specification|
|negative regulation of apoptotic signaling pathway|
|regulation of gene expression, epigenetic|
|nuclear chromatin|
|skeletal system morphogenesis|
|cellular response to oxidative stress|
|nuclear body|
|embryonic organ morphogenesis|
|response to antibiotic|
|peptidyl-lysine modification|
|negative regulation of cell cycle process|
|regionalization|
|histone modification|
|covalent chromatin modification|
|in utero embryonic development|
|response to oxidative stress|
|regulation of apoptotic signaling pathway|
|cellular response to drug|
|embryonic organ development|
|pattern specification process|
|skeletal system development|
|response to toxic substance|
|response to inorganic substance|
|embryonic morphogenesis|
|negative regulation of cell cycle|
|chordate embryonic development|
|embryo development ending in birth or egg hatching|
|DNA-binding transcription factor activity|
|protein ubiquitination|
|chromatin organization|
|regulation of cell cycle process|
|protein modification by small protein conjugation|
|negative regulation of transcription by RNA polymerase II|
|peptidyl-amino acid modification|
|negative regulation of apoptotic process|
|negative regulation of programmed cell death|
|animal organ morphogenesis|
|embryo development|
|protein modification by small protein conjugation or removal|
|negative regulation of cell death|
|response to drug|
|cellular response to oxygen-containing compound|
|chromosome organization|
|regulation of cell cycle|
|negative regulation of transcription, DNA-templated|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|negative regulation of signal transduction|
|negative regulation of RNA metabolic process|
|negative regulation of cell communication|
|negative regulation of signaling|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|DNA binding|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|regulation of apoptotic process|
|negative regulation of biosynthetic process|
|response to oxygen-containing compound|
|regulation of programmed cell death|
|negative regulation of response to stimulus|
|regulation of cell death|
|cellular response to stress|
|negative regulation of gene expression|
\\
=== CRISPR Data ===
No hits were found.
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 2/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|1/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 14000
* **Expression level (log2 read counts)**: 2.87
{{:chemogenomics:nalm6 dist.png?nolink |}}